Record profits for Hikma pharmaceuticals
Hikma pharmaceuticals announced this week its first-half share results, which far exceeded market expectations. In addition, share prices have increased over 46% this year.
The first half results announced this week showed 20% revenue growth and 156% increase in adjusted EPS.
The fast-growing multinational pharmaceutical group focuses on the manufacturing, marketing and sales of generic drugs.
The company is benefitting, in particular, from strong demand for its products in the US and new product launches.
Hikma Pharmaceuticals Interim Results (Press release)
Hikma pharmaceuticals makes record profits (The Telegraph)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.